SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jie Chen, Ling Yan, Feng-Cai Zhu, Jian-Xun Liu, Rong-Cheng Li, Fu-Zhen Wang, Jie Li, Hui Zhuang, Amino acid polymorphism in the reverse transcriptase region of hepatitis B virus and the relationship with nucleos(t)ide analogues treatment for preventing mother-to-infant transmission, Journal of Medical Virology, 2014, 86, 8
  2. 2
    Do Young Kim, Hye Young Chang, Sun Min Lim, Seung Up Kim, Jun Yong Park, Ja Kyung Kim, Kwan Sik Lee, Kwang-Hyub Han, Chae Yoon Chon, Sang Hoon Ahn, Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B, Gut and Liver, 2013, 7, 3, 329

    CrossRef

  3. 3
    A.M. Ismail, P. Samuel, C.E. Eapen, R. Kannangai, P. Abraham, Antiviral Resistance Mutations and Genotype-Associated Amino Acid Substitutions in Treatment-Naïve Hepatitis B Virus-Infected Individuals from the Indian Subcontinent, Intervirology, 2012, 55, 1, 36

    CrossRef

  4. 4
    Bao-Ming Liu, Tong Li, Jie Xu, Xiao-Guang Li, Jian-Ping Dong, Ping Yan, Jing-Xian Yang, Ling Yan, Zhi-Yong Gao, Wen-Peng Li, Xie-Wen Sun, Yu-Hua Wang, Xiu-Juan Jiao, Chun-Sheng Hou, Hui Zhuang, Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients, Antiviral Research, 2010, 85, 3, 512

    CrossRef

  5. 5
    R. A. A. Pondé, D. D. P. Cardoso, M. O. Ferro, The underlying mechanisms for the ‘anti-HBc alone’ serological profile, Archives of Virology, 2010, 155, 2, 149

    CrossRef

  6. 6
    Robert G. Gish, Stephen Locarnini, Genotyping and Genomic Sequencing in Clinical Practice, Clinics in Liver Disease, 2007, 11, 4, 761

    CrossRef

  7. 7
    Stéphanie Villet, Aurélie Ollivet, Christian Pichoud, Luc Barraud, Jean-Pierre Villeneuve, Christian Trépo, Fabien Zoulim, Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient, Journal of Hepatology, 2007, 46, 3, 531

    CrossRef

  8. 8
    J. Sheldon, B. Rodès, F. Zoulim, A. Bartholomeusz, V. Soriano, Mutations affecting the replication capacity of the hepatitis B virus, Journal of Viral Hepatitis, 2006, 13, 7
  9. 9
    C. E. Westland, H. Yang, W. E. Delaney, M. Wulfsohn, N. Lama, C. S. Gibbs, M. D. Miller, J. Fry, C. L. Brosgart, E. R. Schiff, S. Xiong, Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients, Journal of Viral Hepatitis, 2005, 12, 1
  10. 10
    Xuan Xiao, Shihuang Shao, Yongsheng Ding, Zhengde Huang, Xiaojing Chen, Kuo-Chen Chou, An application of gene comparative image for predicting the effect on replication ratio by HBV virus gene missense mutation, Journal of Theoretical Biology, 2005, 235, 4, 555

    CrossRef

  11. 11
    Robert G. Gish, Current Treatment and Future Directions in the Management of Chronic Hepatitis B Viral Infection, Clinics in Liver Disease, 2005, 9, 4, 541

    CrossRef

  12. 12
    Marion G. Peters, H.W. Hann, Paul Martin, E.Jenny Heathcote, P. Buggisch, R. Rubin, M. Bourliere, K. Kowdley, C. Trepo, D.F. Gray, M. Sullivan, K. Kleber, R. Ebrahimi, S. Xiong, Carol L. Brosgart, Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ)., Gastroenterology, 2004, 126, 1, 91

    CrossRef

  13. 13
    H. M. Younger, A. J. Bathgate, P. C. Hayes, Review article: nucleoside analogues for the treatment of chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2004, 20, 11-12
  14. 14
    James R Jacob, Brent E Korba, Paul J Cote, Ilia Toshkov, William E Delaney IV, John L Gerin, Bud C Tennant, Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model, Antiviral Research, 2004, 63, 2, 115

    CrossRef

  15. 15
    Franck Le Guerhier, Alexandre Thermet, Sylvianne Guerret, Michèle Chevallier, Catherine Jamard, Craig S. Gibbs, Christian Trépo, Lucyna Cova, Fabien Zoulim, Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model, Journal of Hepatology, 2003, 38, 3, 328

    CrossRef

  16. 16
    Jeffrey J. Germer, Michael R. Charlton, Michael B. Ishitani, Curtis D. Forehand, Robin Patel, Characterization of Hepatitis B Virus Surface Antigen and Polymerase Mutations in Liver Transplant Recipients Pre- and Post-Transplant, American Journal of Transplantation, 2003, 3, 6
  17. 17
    Louise Cooley, Joseph Sasadeusz, Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1, Journal of Clinical Virology, 2003, 26, 2, 185

    CrossRef

  18. 18
    Stephen Locarnini, Hepatitis B viral resistance: mechanisms and diagnosis, Journal of Hepatology, 2003, 39, 124

    CrossRef

  19. 19
    Louise Cooley, Anna Ayres, Angeline Bartholomeusz, Sharon Lewin, Suzanne Crowe, Anne Mijch, Stephen Locarnini, Joseph Sasadeusz, Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV–HBV co-infected individuals, AIDS, 2003, 17, 11, 1649

    CrossRef

  20. 20
    P Halfon, S Pol, M Bourlière, J Courcambeck, P Cacoub, Résistance aux analogues de nucléosides dans le traitement de l’hépatite chronique B, La Revue de Médecine Interne, 2003, 24, 12, 786

    CrossRef

  21. 21
    Ruth Chin, Stephen Locarnini, Treatment of chronic hepatitis B: current challenges and future directions, Reviews in Medical Virology, 2003, 13, 4
  22. 22
    Angeline Bartholomeusz, Phillip Furman, Stephen Locarnini, Frontiers in Viral Hepatitis, 2003,

    CrossRef

  23. 23
    Jordan Feld, Stephen Locarnini, Antiviral therapy for hepatitis B virus infections: new targets and technical challenges, Journal of Clinical Virology, 2002, 25, 3, 267

    CrossRef

  24. 24
    Nanhua Yao, Zhi Hong, Johnson Y.N. Lau, Application of structural biology tools in the study of viral hepatitis and the design of antiviral therapy, Gastroenterology, 2002, 123, 4, 1350

    CrossRef

  25. 25
    Max Arens, Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV, Journal of Clinical Virology, 2001, 22, 1, 11

    CrossRef

  26. 26
    G. V. Papatheodoridis, S. J. Hadziyannis, Diagnosis and management of pre-core mutant chronic hepatitis B, Journal of Viral Hepatitis, 2001, 8, 5
  27. 27
    Karl P Fischer, Klaus S Gutfreund, D.Lorne Tyrrell, Lamivudine resistance in hepatitis B: mechanisms and clinical implications, Drug Resistance Updates, 2001, 4, 2, 118

    CrossRef

  28. 28
    B Werle, F Zoulim, Nouveaux traitements de l'hépatite B et techniques d'étude de la résistance virale, Immuno-analyse & Biologie Spécialisée, 2001, 16, 3, 158

    CrossRef

  29. 29
    Leonieke M. M. Wolters, Hubert G. M. Niesters, Robert A. de Man, Nucleoside analogues for chronic hepatitis B, European Journal of Gastroenterology & Hepatology, 2001, 13, 12, 1499

    CrossRef

  30. 30
    Y Benhamou, M Bochet, V Thibault, V Calvez, MH Fievet, P Vig, CS Gibbs, C Brosgart, J Fry, H Namini, C Katlama, T Poynard, Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study, The Lancet, 2001, 358, 9283, 718

    CrossRef

  31. 31
    Tim Shaw, Stephen Locarnini, Combination Chemotherapy for Hepatitis B Virus, Drugs, 2000, 60, 3, 517

    CrossRef

  32. 32
    C.Y. William Tong, Genetic variations of hepatitis B virus, Current Opinion in Infectious Diseases, 2000, 13, 5, 481

    CrossRef

  33. 33
    C Ying, E De Clercq, J Neyts, Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus, Antiviral Research, 2000, 48, 2, 117

    CrossRef